PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1518526
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1518526
Chemotherapy-Induced Neutropenia Treatment Market - By Treatment Type (G-CSF, Antibiotics, Granulocyte Transfusion, Antifungals), Drug Type (Branded, Biosimilars), Route of administration (Parenteral, Oral), Distribution Channel & Forecast, 2024 - 2032
The global chemotherapy-induced neutropenia treatment market size will register 3.7% CAGR during 2024-2032, owing to favorable regulatory pathways for approval of biosimilars and growing acceptance among prescribers and patients.
Prevalence of chronic diseases including cancer is a major growth factor for the market. According to the CDC report, in the US, 1.7 million people are diagnosed with cancer annually, with over 600,000 fatalities, making it the second leading cause of death. The cost of cancer care is continually increasing and is projected to exceed $240 billion by 2030. As the cases of cancer surge worldwide, so does the use of chemotherapy as a treatment modality, increasing the likelihood of chemotherapy-induced neutropenia (CIN). This growing demand for rational management of CIN highlights the viability of innovative treatment options such as biosimilars. By providing cost-effective alternatives to conventional treatments, biosimilars address the growing need for accessible and cost-effective neutropenia treatments, which is driving market growth.
Chemotherapy-induced neutropenia treatment industry is classified based on treatment type, drug type, route of administration, distribution channel, and region.
The biosimilars segment will grow rapidly through 2032, as they offer cost-effective alternative to conventional therapies. The increasing availability of biosimilars for the treatment of neutropenia has given healthcare providers the opportunity to optimize treatment regimens while reducing healthcare costs. Additionally, as healthcare infrastructure worldwide is under increased pressure to contain costs without compromising patient care, the introduction of biosimilars is an attractive solution to lighten the financial burden while maintaining safety standards, which will drive growth in the segment.
The oral formulations segment will grow moderately during 2024-2032, due to the convenience and flexibility. The development of oral solutions to treat neutropenia enable patient-centered treatments so that people can receive treatment on an outpatient basis or even in the comfort of their own home. In addition, innovations in drug delivery techniques have increased the bioavailability and pharmacokinetics of oral formulations, further increasing their use.
Europe chemotherapy-induced neutropenia treatment industry size will grow strongly between 2024 and 2032, due to robust healthcare infrastructure and high incidence of cancer. Countries such as Germany, the United Kingdom and France are leading industry growth, fueled by investments in oncology and the adoption of advanced treatments. In addition, collaboration between pharmaceutical companies and research institutes enables the development & commercialization of new treatments for neutropenia. The region's proactive approach to cancer treatment and favorable policies contribute to its notable position in the global market.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of cancer
- 3.2.1.2 Growing adoption of chemotherapy
- 3.2.1.3 Technological advancements in treatment options
- 3.2.1.4 Rising government initiatives and funding
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of treatment
- 3.2.2.2 Adverse effects of treatment
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
- 3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Granulocyte colony-stimulating factor therapy
- 5.3 Antibiotics
- 5.4 Granulocyte transfusion
- 5.5 Antifungals
- 5.6 Other treatment types
Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Branded
- 6.3 Biosimilars
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Parenteral
- 7.3 Oral
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Amgen Inc.
- 10.2 BeyondSpring Inc.
- 10.3 Biocon Biologics Inc.
- 10.4 Cellerant Therapeutics
- 10.5 Coherus BioSciences, Inc.
- 10.6 Evive Biotech
- 10.7 Kyowa Kirin Co., Ltd.
- 10.8 Novartis AG
- 10.9 Pfizer Inc.
- 10.10 Sanofi
- 10.11 Spectrum Pharmaceuticals
- 10.12 Teva Pharmaceutical Industries Ltd.
